Quality of life with pharmacological treatment in patients with benign prostatic enlargement : results from the Evolution European Prospective Multicenter Multi-National Registry Study

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Caris A.) > (2020-2023) > Quality of life wit...

LIBRIS Formathandbok (Information om MARC21)

Fältnamn	Indikatorer	Metadata
000		04303naa a2200421 4500
001		oai:lup.lub.lu.se:09767718-4bb2-4c30-ae64-795df65cb77d
003		SwePub
008		200615s2021 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
024	7	a https://lup.lub.lu.se/record/09767718-4bb2-4c30-ae64-795df65cb77d2 URI
024	7	a https://doi.org/10.1007/s00345-020-03219-72 DOI
040		a (SwePub)lu
041		a engb eng
042		9 SwePub
072	7	a art2 swepub-publicationtype
072	7	a ref2 swepub-contenttype
100	1	a Bhatt, Nikita R.u Ipswich Hospital NHS Trust4 aut
245	1 0	a Quality of life with pharmacological treatment in patients with benign prostatic enlargement : results from the Evolution European Prospective Multicenter Multi-National Registry Study
264		c 2020-05-04
264	1	b Springer Science and Business Media LLC,c 2021
520		a Background: Lower urinary tract symptoms due to benign prostate enlargement (LUTS/BPE) can lead to significant disturbances to health-related quality of life (HRQoL) and psychological well-being. The aim of this study was to evaluate the effect of pharmacological treatment of LUTS/BPE on disease specific and generic QOL measures. Methods: Evolution was a European prospective, multicenter multi-national, observational registry collecting real-life clinical data over 2 years on the management of LUTS/BPE in primary and secondary care. This study investigated disease-specific QOL using questionnaires such as IPSS Q8, BPH Impact Index (BII) and generic QOL using questionnaires like EuroQOL Five Dimension (EQ5D) which encompassed EQ5D VAS and EQ5D health index. Results: The registry enrolled 1838 BPE patients and 1246 patients were evaluable at the end of 24 months. Nearly 70% of patients in the study were previously treated with medical therapy and 17% of these had already discontinued medical treatment previously for various reasons with lack of efficacy being the most common. The mean time since diagnosis of LUTS in the previously treated group was 4.7 years (0–26 years). Medical management produced statistically significant improvement in QOL (disease specific and generic) in previously untreated patients and an insignificant change in generic QOL in previously treated patients. Conclusions: After 5-years from the onset of symptoms, LUTS/BPE patients previously treated with medication had significantly impaired QOL in patients in a manner comparable to other chronic diseases. Earlier intervention with minimally invasive surgical techniques (MIT) should be considered in LUTS/BPE patients that do not show a significant improvement in QOL with medical therapy.
650	7	a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Urologi och njurmedicin0 (SwePub)302142 hsv//swe
650	7	a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Urology and Nephrology0 (SwePub)302142 hsv//eng
653		a IPSS
653		a Lower urinary tract symptoms
653		a Medical treatment
653		a Registry
700	1	a Davis, Niall F.u Beaumont Hospital, Dublin,Royal College of Surgeons in Ireland4 aut
700	1	a Witjes, W. P.u European Association of Urology, Research Foundation4 aut
700	1	a Bjartell, A.u Lund University,Lunds universitet,Urologisk cancerforskning, Malmö,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Urological cancer, Malmö,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,European Association of Urology, Research Foundation4 aut0 (Swepub:lu)kir-abj
700	1	a Caris, C.u European Association of Urology, Research Foundation4 aut
700	1	a Patel, A.u Spire London East Hospital4 aut
700	1	a de la Taille, A.u Henri Mondor Hospital4 aut
700	1	a Tubaro, A.u Sant'Andrea Hospital,Sapienza University of Rome4 aut
710	2	a Ipswich Hospital NHS Trustb Beaumont Hospital, Dublin4 org
773	0	t World Journal of Urologyd : Springer Science and Business Media LLCg 39:2, s. 517-526q 39:2<517-526x 0724-4983x 1433-8726
856	4	u http://dx.doi.org/10.1007/s00345-020-03219-7y FULLTEXT
856	4 8	u https://lup.lub.lu.se/record/09767718-4bb2-4c30-ae64-795df65cb77d
856	4 8	u https://doi.org/10.1007/s00345-020-03219-7

Hitta via bibliotek

World Journal of Urology (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Bhatt, Nikita R.; Davis, Niall F.; Witjes, W. P.; Bjartell, A.; Caris, C.; Patel, A.; visa fler...; de la Taille, A.; Tubaro, A.; visa färre...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Urologi och njur ...

Artiklar i publikationen: World Journal of ...

Av lärosätet: Lunds universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se